Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
- Conditions
- Prostate Cancer
- Registration Number
- NCT00140348
- Lead Sponsor
- Cell Genesys
- Brief Summary
The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 80
- Diagnosis of adenocarcinoma of the prostate
- Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy
- Detectable metastases
- ECOG performance status of 0 or 1
- Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer
- Significant cancer related pain
- Prior gene therapy, chemotherapy, or immunotherapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (12)
South Florida Medical Research
🇺🇸Aventura, Florida, United States
Northeast Indiana Research
🇺🇸Fort Wayne, Indiana, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Fox Chase cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Emory University
🇺🇸Atlanta, Georgia, United States
UCSF
🇺🇸San Francisco, California, United States
West Coast Clinical Research
🇺🇸Tarzana, California, United States
University of Michigan Medical Center
🇺🇸Ann Arbor, Michigan, United States
Urology San Antonio
🇺🇸San Antonio, Texas, United States
South Orange County Medical Research Center
🇺🇸Laguna Woods, California, United States
Carle Cancer Center
🇺🇸Urbana, Illinois, United States
Virginia Mason Med. Crt.
🇺🇸Seattle, Washington, United States